CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0.93×, higher than 95% of its Biotechnology peers (median 0.09×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
516.72MUSDvs all stocks (USD)
Revenue (TTM)
151.40MUSDvs all stocks (USD)
Profit Margin
-201.05%vs Biotechnology peers
Beta
1.78xvs all stocks
52-Week Change
-30.12%vs all stocks
Market Capitalization
516.72MUSDvs all stocks (USD)
Enterprise Value
553.96MUSDvs all stocks (USD)
Forward P/E
-2.46xvs Biotechnology peers
Price to Sales (TTM)
3.41xvs Biotechnology peers
Price to Book (MRQ)
1.10xvs Biotechnology peers
Enterprise to Revenue
3.66xvs Biotechnology peers
Enterprise to EBITDA
-2.11xvs Biotechnology peers
Gross Margin
84.09%vs Biotechnology peers
Profit Margin
-201.05%vs Biotechnology peers
Operating Margin
-366.51%vs Biotechnology peers
Return on Assets (TTM)
-16.16%vs Biotechnology peers
Return on Equity (TTM)
-56.03%vs Biotechnology peers
Revenue (TTM)
151.40MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.67USDUpdated Jul 18, 2026Quarterly Revenue Growth
-49.10%vs Biotechnology peers
Gross Profit (TTM)
105.42MUSDvs all stocks (USD)
EBITDA (TTM)
-262.49MUSDvs all stocks (USD)
Net Income (TTM)
-305.51MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-59.70%vs Biotechnology peers
Operating Cash Flow (TTM)
-166.22MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.93MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
170.16MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
46.97MUSDFY2025 · Dec 31, 2025Gross Profit
123.18MUSDFY2025 · Dec 31, 2025Operating Income
-303.88MUSDvs all stocks (USD)
Pre-tax Income
-313.60MUSDFY2025 · Dec 31, 2025Income Tax Expense
-837.00KUSDFY2025 · Dec 31, 2025Net Income
-312.76MUSDFY2025 · Dec 31, 2025EBIT
-313.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-226.80MUSDFY2025 · Dec 31, 2025Research & Development
243.77MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
183.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-5.64USDFY2025 · Dec 31, 2025EPS (Diluted)
-5.64USDFY2025 · Dec 31, 2025Basic Shares Outstanding
55.46MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.46MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-312.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-189.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-196.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
212.37MUSDFY2025 · Dec 31, 2025Income Tax Paid
192.00KUSDFY2025 · Dec 31, 2025Interest Paid
4.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-312.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
58.99MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.36MUSDFY2025 · Dec 31, 2025Stock-based Compensation
81.55MUSDFY2025 · Dec 31, 2025Other Non-cash Items
33.60MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.47MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.99MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-44.75MUSDFY2025 · Dec 31, 2025Capital Expenditures
-7.09MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-418.63MUSDFY2025 · Dec 31, 2025Sale of Investments
185.38MUSDFY2025 · Dec 31, 2025Other Investing Activity
50.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-240.29MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-354.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
17.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
58.21MSharesUpdated Jul 18, 2026Float Shares
47.85MSharesUpdated Jul 18, 2026Shares Short
5.16MSharesUpdated Jul 18, 2026Short Ratio
3.72daysvs all stocks
Short % of Shares Outstanding
10.00%vs all stocks
% Held by Insiders
4.60%vs all stocks
% Held by Institutions
68.68%vs all stocks
Total Cash (MRQ)
373.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.72USDUpdated Jul 18, 2026Total Debt (MRQ)
410.70MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9268xvs Biotechnology peers
Current Ratio (MRQ)
5.15xvs Biotechnology peers
Book Value per Share (MRQ)
7.19USDUpdated Jul 18, 2026Total Assets
1.12BUSDvs all stocks (USD)
Total Current Assets
471.84MUSDFY2025 · Dec 31, 2025Total Liabilities
611.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
647.86MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
515.14MUSDFY2025 · Dec 31, 2025Total Current Liabilities
95.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
167.20MUSDFY2025 · Dec 31, 2025Other Short-term Investments
255.42MUSDFY2025 · Dec 31, 2025Accounts Receivable
24.03MUSDFY2025 · Dec 31, 2025Accounts Payable
10.57MUSDFY2025 · Dec 31, 2025Short-term Debt
22.81MUSDFY2025 · Dec 31, 2025Deferred Revenue
19.98MUSDFY2025 · Dec 31, 2025Other Current Liabilities
27.05MUSDFY2025 · Dec 31, 2025Long-term Debt
417.08MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
22.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-6.15BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
508.59MUSDvs all stocks (USD)
52-Week Low
5.37USDUpdated Jul 18, 202652-Week High
17.58USDUpdated Jul 18, 202652-Week Change
-30.12%vs all stocks
Beta
1.78xvs all stocks
50-Day MA
8.87USDUpdated Jul 18, 2026200-Day MA
9.20USDUpdated Jul 18, 2026Avg 10-Day Volume
1.03MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.22MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-5.38USDUpdated Jul 18, 2026Other Income / Expense
-32.34MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Rising Operating Income With Falling Gross Profit and Shrinking Assets
Operating income has risen while gross profit and the asset base both shrank.
Reads
Diagnostic
Operating Income Up Despite Gross Profit Decline, Margins Elevated
Operating income keeps rising while gross profit falls, so the gain sits below that line.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0.93×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 0.93Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.84Profit Margin: -2.01
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Model Organisms Center Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
PureTech Health plc
Tier 1ProductionApproval-Gated PipelineRiskInterface
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Angi Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedRising Operating Income With Falling Gross Profit and Shrinking AssetsOperating Income Up Despite Gross Profit Decline, Margins Elevated
Ecopro BM. Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
KC Tech Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated